Procter & Gamble Health Limited — PPTs, 16-06-2025: Investor Presentation

1. Financial Highlights:

Procter & Gamble Health Limited reported 8% sales growth and a 27% rise in PAT over nine months, with net sales around INR 1,220 Cr (annualized) and PAT near INR 255 Cr (annualized). ROE improved by 34% over five years, highlighting strong profitability and capital efficiency. Productivity initiatives delivered INR 40 Cr cost savings, supporting stable margins.

2. Strategic Initiatives & Growth Drivers:

The company is executing an integrated growth strategy across five key areas: consumer value, product, packaging, communication, and retail execution. Focused investments in rural expansion, distributor networks, and e-commerce channels aim to capture emerging demand. Cost efficiencies in materials, manufacturing, advertising, and overheads are reinvested to fuel growth.

3. Business Developments:

Top brands like Neurobion and Evion are enhanced via improved packaging, communication, and retail execution to boost market presence. Community health efforts, including mobile health units and maternal-child nutrition programs, reinforce social responsibility commitments.

4. Market Position & Competitive Advantage:

As a leader in the Vitamins, Minerals & Supplements sector, the company benefits from steady category growth and growing e-commerce penetration. Its multi-vector superiority framework strengthens brand appeal, while scale and productivity offer cost advantages.

5. Investor Implications:

Robust revenue and margin gains, alongside disciplined capital use and focus on digital and rural markets, indicate positive growth potential. Efficient execution of its growth strategy mitigates risks, positioning the company well to leverage increasing health awareness in India.